NCT04393948

Lung Irradiation for COVID-19 Pneumonia

Pilot Study of Low-Dose Single or Bilateral Whole Lung Irradiation for SARS-CoV-2 Pneumonia

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

In this research study the investigators want to learn more about the potential benefit of radiation to the lung to improve the health of patients who are hospitalized with Coronavirus-19 (COVID-19) due to infection with a virus called SARS-CoV-2. This infection causes inflammation of the lung, which can make it difficult to breathe. As a result, patients may need supplemental oxygen or be placed on a ventilator. The investigators believe that low dose radiation therapy to the lung may reduce this inflammation and increase the likelihood that patients will need less oxygen support such as ventilation or supplemental oxygen, or be discharged from the hospital in fewer days, compared to without radiation therapy. The amount of radiation is much lower than what is typically used to treat other conditions such as cancer, although it is higher than the dose used for routine medical imaging.

Conditions

• SARS-CoV 2

Interventions

Type	Name	Description
RADIATION	Phase 1	Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
RADIATION	Phase 1	Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
RADIATION	Phase 2	Arm A - No irradiation
RADIATION	Phase 2	Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
RADIATION	Phase 2	Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator

Timeline

• Start date: 2020-06-19
• Primary completion: 2021-06-01
• Completion: 2021-09-01
• First posted: 2020-05-19
• Last updated: 2022-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study